NexJenner is a specialized service company that supports the entire pharmaceutical development cycle based on a unique technological platform for new drug development and drug delivery.
As a pharmaceutical development specialist, NexJenner develops and offers services for new drugs based on technologies such as Drug-Drug Conjugation, Antibody Drug Conjugation, CAR-T, CAR-NK, vaccines, and ASO.

Furthermore, as a specialist in the development of DDS (Drug Delivery System), NexJenner designs and provides services for DDS formulations such as LNP and Liposome, based on technologies including Lipoprotein synthesis, oligonucleotide synthesis, and antibody design and production.

Led by CEO Kim Su Dong, NexJenner maintains a close industry-academia-research-hospital network, supporting the pharmaceutical sector in (non) clinical translational studies, DMF, CMC, and regulatory document preparation for raw material medicine, as well as (non) clinical sample production via BGMP.